- Home
- GMM vs ANL Comparison
GMM vs ANL Comparison
Compare GMM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GMM | ANL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 52.0M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GMM | ANL |
|---|---|---|
| Price | $1.34 | $0.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.6K | 13.2K |
| Earning Date | 08-18-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.75 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $0.88 |
| 52 Week High | $4.97 | $2.99 |
Technical Indicators
Market Signals| Indicator | GMM | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 22.30 |
| Support Level | $1.25 | $1.32 |
| Resistance Level | $1.59 | $1.59 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 22.01 | 5.70 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.